Willem A van Gool
Overview
Explore the profile of Willem A van Gool including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
135
Citations
4500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoevenaar-Blom M, Shourik J, Shourick J, van Dalen J, van Gool W, Andrieu S, et al.
Alzheimers Dement
. 2025 Jan;
21(2):e14557.
PMID: 39868821
Introduction: We explored which dementia risk factors in two multidomain prevention trials mediate beneficial, neutral, or counteracting effects on dementia incidence. Methods: We pooled data from the multidomain MAPT (Multidomain...
2.
Coley N, Hoevenaar-Blom M, Shourick J, Moll van Charante E, van Dalen J, van Gool W, et al.
Alzheimers Dement
. 2025 Jan;
21(2):e14472.
PMID: 39821948
Introduction: It is unknown in which, if any, subgroups of older adults multidomain interventions are effective at reducing long-term dementia incidence. Methods: We pooled up to 12 years of follow-up...
3.
Schroevers J, Hoevenaar-Blom M, Busschers W, Hollander M, van Gool W, Richard E, et al.
Lancet Reg Health Eur
. 2024 Dec;
47:101132.
PMID: 39633892
[This corrects the article DOI: 10.1016/j.lanepe.2024.100927.].
4.
Schroevers J, Richard E, Hoevenaar-Blom M, van den Born B, van Gool W, Moll van Charante E, et al.
J Am Med Dir Assoc
. 2024 Jul;
25(9):105132.
PMID: 38977201
Objective: Midlife dyslipidemia is associated with higher risk of dementia in late-life dementia, but the impact of late-life dyslipidemia on dementia risk is uncertain. This may be due to the...
5.
Schroevers J, Hoevenaar-Blom M, Busschers W, Hollander M, van Gool W, Richard E, et al.
Lancet Reg Health Eur
. 2024 May;
42:100927.
PMID: 38800111
Background: Hypertension is a modifiable risk factor for dementia affecting over 70% of individuals older than 60. Lowering dementia risk through preferential treatment with antihypertensive medication (AHM) classes that are...
6.
Lindhout J, Richard E, Hafdi M, Perry M, Moll van Charante E, van Gool W
J Am Med Dir Assoc
. 2024 May;
25(7):105040.
PMID: 38796169
Objectives: Dementia is a clinical diagnosis without curative treatment. It is uncertain whether ancillary testing is beneficial for patients. This study investigates the association between use of diagnostic tests and...
7.
Moll van Charante E, Hoevenaar-Blom M, Song M, Andrieu S, Barnes L, Birck C, et al.
Lancet Healthy Longev
. 2024 May;
5(6):e431-e442.
PMID: 38763155
Background: The expected increase of dementia prevalence in the coming decades will mainly be in low-income and middle-income countries and in people with low socioeconomic status in high-income countries. This...
8.
Ottens T, Hermes C, Page V, Oldham M, Arora R, Bienvenu 3rd O, et al.
Delirium (Bielef)
. 2024 Feb;
2024.
PMID: 38348284
Delirium is common in hospitalised patients, and there is currently no specific treatment. Identifying and treating underlying somatic causes of delirium is the first priority once delirium is diagnosed. Several...
9.
den Brok M, van Dalen J, Marcum Z, Busschers W, van Middelaar T, Hilkens N, et al.
JAMA Netw Open
. 2023 Oct;
6(10):e2340249.
PMID: 37902753
Importance: High visit-to-visit blood pressure variability (BPV) in late life may reflect increased dementia risk better than mean systolic blood pressure (SBP). Evidence from midlife to late life could be...
10.